ArticleBMC pulmonary medicine2026
Serum KL-6 combined with immune/inflammatory biomarkers identifies complicated silicosis.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundComplicated silicosis (CS) poses significant diagnostic challenges, with current diagnosis relying heavily on radiographic imaging. These challenges highlight a need for reliable non-invasive biomarkers to improve early detection and disease staging. This study aimed to evaluate serum Krebs von den Lungen-6 (KL-6) levels in silicosis patients across different disease stages and explore their association with immune-inflammatory markers to assess its potential as a biomarker for early diagnosis and risk stratification.
methodsThis study enrolled individuals evaluated at our institution between October 2022 and June 2025 and categorized them into three groups: dust-exposed workers without silicosis (DEWs), patients with simple silicosis (SS), and those with CS. Serum levels of KL-6, interleukin (IL)-6, IL-8, IL-10, CD8+ T cells, and other inflammatory markers were measured, and the erythrocyte sedimentation rate (ESR) was assessed alongside pulmonary function tests. Receiver operating characteristic (ROC) curves and correlation analyses were used to assess diagnostic performance and biomarker associations.
resultsIn total, 135 individuals were enrolled in this study. Of these, 25 were categorized as DEWs, 33 as patients with SS, and 77 with CS. Patients with CS were younger than those with SS (median age: 59.0 vs. 68.0 years) and had a shorter exposure duration (mean: 16 vs. 18 years) but worse lung function. KL-6 levels increased progressively across groups, peaking in the CS group (SS vs. CS: median, 257.00 vs. 441.22 U/mL; IQR: 202.96–358.50 vs. 295.53–926.50 U/mL). KL-6 was negatively correlated with FVC%, FEV1%, and DLCO% and positively correlated with lactate dehydrogenase (LDH) (r = 0.57) and ESR (r = 0.44). At a cutoff of 300 U/mL, KL-6 distinguished CS from SS with an area under the curve (AUC) of 0.756 (sensitivity, 75.3%; specificity, 69.7%) and performed better in distinguishing CS from DEWs (AUC = 0.842; sensitivity, 74%; specificity, 84%). A combined model of KL-6, LDH, and ESR further improved diagnostic accuracy (AUC = 0.914; sensitivity, 85.7%; specificity, 80.0%).
conclusionsSerum KL-6 is strongly associated with pulmonary function decline and systemic inflammation in silicosis. When combined with LDH and ESR, it significantly enhances diagnostic precision, offering a promising non-radiological biomarker panel for disease staging and early identification of disease severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.